WO2013078264A1 - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations Download PDF

Info

Publication number
WO2013078264A1
WO2013078264A1 PCT/US2012/066185 US2012066185W WO2013078264A1 WO 2013078264 A1 WO2013078264 A1 WO 2013078264A1 US 2012066185 W US2012066185 W US 2012066185W WO 2013078264 A1 WO2013078264 A1 WO 2013078264A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
solid
solid oral
oral pharmaceutical
phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/066185
Other languages
English (en)
French (fr)
Inventor
Daya Verma
Yogita Krishnamachari
Xiaohong SHEN
Hanchen LEE
Ping Li
Rajinder Singh
LayChoo TAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47501412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2013078264(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SM20180595T priority Critical patent/SMT201800595T1/it
Priority to EP18188984.1A priority patent/EP3449911B8/en
Priority to HK14110469.5A priority patent/HK1197024B/en
Priority to CA2856406A priority patent/CA2856406C/en
Priority to JP2014543550A priority patent/JP6216325B2/ja
Priority to BR112014011981A priority patent/BR112014011981B8/pt
Priority to SI201231455T priority patent/SI2782557T1/sl
Priority to RS20181376A priority patent/RS58048B1/sr
Priority to CN201280056985.9A priority patent/CN103945831A/zh
Priority to EP12809882.9A priority patent/EP2782557B1/en
Priority to LTEP12809882.9T priority patent/LT2782557T/lt
Priority to ES12809882T priority patent/ES2695099T3/es
Priority to NZ623628A priority patent/NZ623628B2/en
Priority to US14/359,121 priority patent/US9387208B2/en
Priority to SG11201401260QA priority patent/SG11201401260QA/en
Priority to DK12809882.9T priority patent/DK2782557T3/en
Application filed by Novartis AG filed Critical Novartis AG
Priority to EA201491007A priority patent/EA025389B1/ru
Priority to HRP20181896TT priority patent/HRP20181896T1/hr
Priority to PL12809882T priority patent/PL2782557T3/pl
Priority to AU2012340759A priority patent/AU2012340759C1/en
Priority to UAA201403227A priority patent/UA115039C2/uk
Priority to KR1020147013457A priority patent/KR102091295B1/ko
Priority to MX2014006278A priority patent/MX353446B/es
Publication of WO2013078264A1 publication Critical patent/WO2013078264A1/en
Priority to ZA2014/02418A priority patent/ZA201402418B/en
Priority to TNP2014000145A priority patent/TN2014000145A1/en
Priority to IL232305A priority patent/IL232305B/en
Priority to MA37033A priority patent/MA35716B1/fr
Priority to PH12014501157A priority patent/PH12014501157A1/en
Anticipated expiration legal-status Critical
Priority to US15/179,190 priority patent/US9763941B2/en
Priority to US15/452,239 priority patent/US10258622B2/en
Priority to US15/921,306 priority patent/US10561654B2/en
Priority to CY20181101222T priority patent/CY1121421T1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to solid oral pharmaceutical formulations of (S)-methyl (1- ((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-l-isopropyl-lH-pyrazol-4- yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (COMPOUND A) and the use of these formulations for treating proliferative diseases, such as solid tumor diseases.
  • the COMPOUND A has the chemical structure:
  • COMPOUND A is a BCS class II compound exhibiting poor aqueous solubility at weakly acidic and neutral pH which poses a challenge for oral bioavailability and therapeutic effect.
  • the compound exhibits typical weak base solubility characteristics and is highly soluble at low pH, starts to decline at around pH 3.0 and remains low at intrinsic solubility level over the range of neutral pH.
  • COMPOUND A Upon emptying from the stomach, COMPOUND A has the tendency to quickly precipitate out of solution due to an abrupt solubility drop in intestinal pH. This significantly reduces COMPOUND A that is available for intestinal absorption.
  • the present invention relates to orally bioavailable pharmaceutical solid dispersion formulations of COMPOUND A.
  • Figure 1 represents the 2 stage dissolution profile of the formulation described in Example 1.
  • Figure 2 represents the 2-Stage (pH 2 first 60 min to 6.8 after 60 min) dissolution of the formulations described in Examples 2-7.
  • Figure 3 represents the dissolution profile of the tablet formulation described in Example 8.
  • COMPOUND A is a BCS class II compound which exhibits typical weak base solubility characteristics: higher solubility at low pH, and limited solubility around neutral pH. Therapeutic compounds with such solubility characteristics typically present pharmaceutical formulation scientists with a challenge while attempting to prepare oral formulations capable of improving oral bioavailability of the therapeutic compound. Such challenges in preparing solid oral dosage forms of COMPOUND A are overcome, according to the present invention, by formulating the compound as a solid dispersion.
  • Solid dispersions are specialized pharmaceutical formulations.
  • the most suitable solid dispersion formulation is the one that enhances solubility and dissolution rate and maintains the stability of the drug substance in an amorphous state.
  • the drug substance is uniformly dispersed in a solid matrix which promotes dissolution of the drug in the gastrointestinal tract and maintains the drug in a high energy amorphous state.
  • Pharmaceutical solid dispersions are produced by techniques known in the art, for example, solvent evaporation, kneading and melt extrustion.
  • an inner phase is prepared.
  • the inner phase is a solid dispersion comprising COMPOUND A in a suitable polymer matrix, which is composed, for example, of a hydrophilic binder, a surfactant and optional additional excipients, which are known in the art, followed by milling to reduce particle size.
  • the inner phase Prior to tableting or encapsulation, the inner phase is preferably combined with additional excipients, which are collectively referred to herein as the external phase.
  • additional excipients which are collectively referred to herein as the external phase.
  • One or more of an acidifier, a filler, a disintegrant, a flow enhancer and a lubricant are typically included in the external phase.
  • the present invention relates to a solid oral pharmaceutical formulation which comprises a solid dispersion comprising COMPOUND A.
  • the present invention is a solid oral pharmaceutical formulation which comprises:
  • the internal phase or, more preferably, the external phase comprises an acidifier.
  • the present invention further relates to a solid oral pharmaceutical formulation which comprises:
  • the present invention is a solid oral pharmaceutical formulation which comprises:
  • an external phase which comprises one or more of an acidifier, a filler, a disintegrant, a flow enhancer and a lubricant.
  • the hydrophilic binder should be suitable for complete miscibility with COMPOUND A and upon formulation dissolution, serve as a precipitation inhibitor of COMPOUND A.
  • Suitable hydrophilic binders for inclusion in the inner phase include copovidone, hydroxypropylmethylcellulose, polyvinylpyrrolidone, hydroxypropylcellulose, and methacrylate copolymer, polyethylene oxide, HPMC acetate succinate, HPMC phthalate. Copovidone is especially useful as the hydrophilic binder.
  • KOLLIDON VA64 which is a copolymer of l-vinyl-2- pyrrolidone and vinyl acetate in a ratio of 6:4 by mass and is available from BASF, is highly suitable for use as a hydrophilic binder in the inner phase.
  • the surfactant should be suitable for use in melt extrusion to enhance dissolution and solubilization of COMPOUND A. In some cases, the surfactant may help reduce the process temperature through its plastic izing effect.
  • Suitable surfactants for inclusion in the inner phase include poloxamers, such as Poloxamer 188, sodium lauryl sulphate, Tween 80, sorbitol, polysorbate 20, polysorbate 80, Vitamin E TPGS, and polyethylene glycol.
  • Additional excipients that may optionally be included in the inner phase include acidifiers, and plasticizers.
  • the internal phase or preferably the external phase comprises an acidifier to control the microenvironmental pH in the acidic range.
  • Suitable acidifiers include organic acids such as citric acid, succinic acid, maleic acid, tartaric acid, malic acid and adipic acid.
  • Suitable fillers, disintegrants, flow enhancers and lubricants are known to those of skill in the art.
  • Especially useful fillers include lactose, maltodextrin, mannitol, microcrystalline cellulose, pregelatinized starch, and sucrose esters.
  • Useful disintegrants include crospovidone, croscarmellose sodium, sodium starch glycolate, microcrystalline cellulose, and pregelatinized starch.
  • Useful flow enhancers include colloidal silicon dioxide, talc, magnesium stearate, and mannitol.
  • Useful lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, hydrogenated castor oil, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, zinc stearate, talc, microcrystalline cellulose, and sucrose esters.
  • the inner phase comprises various ranges of %w/w of active agent, hydrophilic binder and surfactant.
  • the present inner phase can comprise 5-70% Compound A, 10-90% of hydrophilic binder, and 5-30% surfactant, preferably 5-50% Compound A, 30-80% of hydrophilic binder, and 5-30% surfactant, more preferably 5-40% Compound A, 50- 80% of hydrophilic binder, and 5-20% surfactant.
  • the external phase comprises various ranges of %w/w of acidifier, filler, disintegrant, flow enhancer and lubricant.
  • the present external phase can comprise 1-70% acidifier, 20-70% filler, 0-30% disintegrant, 0-10% flow enhancer and 0-10% lubricant, preferably 2-60% acidifier, 30-70% filler, 5-20% disintegrant, 0.5-5% flow enhancer and 0.5-5% lubricant, more preferably 10-40% acidifier, 20-40% filler, 1- 15% disintegrant, 1-5% flow enhancer and 1-5% lubricant.
  • the solid oral dosage form for example, capsules or tablets, are a blend of the internal and external phases in a ratio of from 100:0 to 30:70, preferably 80:20 to 40:60, most preferably 75:25 to 50:50.
  • Stabilization of an amorphous form of COMPOUND A in a solid dispersion formulation enhances bioavailability, attributable to a higher dissolution rate and kinetic solubility of the amorphous form in comparison to its crystalline form.
  • COMPOUND A stays in amorphous form, an increase in kinetic solubility and dissolution rate as well as in oral bioavailability is achieved using the solid dispersion formulation.
  • the present invention is formulated as a capsule, such as hard gelatin capsule or a soft elastic capsule.
  • the present invention is in the form of a tablet or a pill.
  • the amount of COMPOUND A can be present in the ranges of 1-1500 mg, 2.5-800 mg, or 5-400 mg, with preferred examples including 10 mg, 20 mg, 25 mg, 50 mg , 100 mg, 200 mg, 400 mg and 500 mg.
  • the solid oral formulations of the present invention can be administered to treat diseases which respond to inhibition of B-RAF, particularly diseases that are characterzed by a mutation in B-RAF, particularly melanoma and colorectal cancer.
  • the present invention further relates to the use of a solid oral pharmaceutical formulation described above for the preparation of a medicament for the treatment of a proliferative disease, especially wherein the proliferative disease is a solid tumor disease characterized by a mutation in B-RAF, such as melanoma or colorectal cancer.
  • the present invention further relates to a method of treating a proliferative disease which comprises administering to a patient in need of treatment a therapeutically effective amount of a formulation described herein, especially wherein the proliferative disease is a solid tumor disease characterized by a mutation in B-RAF, such as melanoma or colorectal cancer.
  • Example 1 The following Examples are intended to illustrate, but not to limit, the invention.
  • composition is prepared at constant drug loading of 15% and formulated into 10, 25, 50 mg and 100 mg capsules.
  • Poloxamer 188 3.3 8.4 16.7 33.3 (Pluronic F68)
  • the processing is performed by hot-melt extrusion using a 18 mm twin-screw Leistriez extruder, followed by milling the extrudates, blending with the external phase and screening. Following blending, the blend is encapsulated into pink hard gelatin capsules of size 0 and 00 for drug doses of 50 and 100 mg respectively.
  • a step-by step approach is shown below:
  • In-vivo monkey PK data with the resulting capsules show bioavailability suitable for oral administration with a mean Cmax of 11833 ng/ml, Tmax at 4 hours and an AUC of 32686 ng*hr/ml.
  • XRPD data indicate physical stability of the amorphous solid dispersion formulation (no indication of conversion to the crystalline drug substance) upon storage at accelerated stability conditions of 40 °C/ 75 % RH for 4 weeks.
  • the present formulation exhibits a glass transition temperature (Tg) of 97 °C which is above the recommended drug product storage temperature of no greater than 30°C, demonstrating physical stability without conversion of the amorphous drug substance into the poorly water soluble crystalline drug substance.
  • Tg glass transition temperature
  • the present formulation shows excellent chemical stability upon storage at accelerated stability conditions at 40 ° C/75 % RH with no evidence of any degradation products and 100% assay content results for COMPOUND A.
  • This formulation exhibits a glass transition temperature (Tg) of 109°C demonstrating physical stability without conversion of the amorphous drug substance into the poorly water soluble crystalline drug substance.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2012/066185 2011-11-23 2012-11-21 Pharmaceutical formulations Ceased WO2013078264A1 (en)

Priority Applications (32)

Application Number Priority Date Filing Date Title
HRP20181896TT HRP20181896T1 (hr) 2011-11-23 2012-11-21 Farmaceutske formulacije
EP18188984.1A EP3449911B8 (en) 2011-11-23 2012-11-21 Pharmaceutical formulations
HK14110469.5A HK1197024B (en) 2011-11-23 2012-11-21 Pharmaceutical formulations
CA2856406A CA2856406C (en) 2011-11-23 2012-11-21 Pharmaceutical formulations
JP2014543550A JP6216325B2 (ja) 2011-11-23 2012-11-21 医薬製剤
BR112014011981A BR112014011981B8 (pt) 2011-11-23 2012-11-21 Formulações farmacêuticas sólidas orais, seus processos de preparação e usos
SI201231455T SI2782557T1 (sl) 2011-11-23 2012-11-21 Farmacevtske formulacije
RS20181376A RS58048B1 (sr) 2011-11-23 2012-11-21 Farmaceutske formulacije
CN201280056985.9A CN103945831A (zh) 2011-11-23 2012-11-21 医药制剂
EP12809882.9A EP2782557B1 (en) 2011-11-23 2012-11-21 Pharmaceutical formulations
LTEP12809882.9T LT2782557T (lt) 2011-11-23 2012-11-21 Farmacinės kompozicijos
ES12809882T ES2695099T3 (es) 2011-11-23 2012-11-21 Formulaciones farmacéuticas
NZ623628A NZ623628B2 (en) 2011-11-23 2012-11-21 Solid oral pharmaceutical formulations comprising amorphous (S)-methyl (1- ((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropy1-1H-pyrazo1-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (Compound A)
US14/359,121 US9387208B2 (en) 2011-11-23 2012-11-21 Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
SG11201401260QA SG11201401260QA (en) 2011-11-23 2012-11-21 Pharmaceutical formulations
DK12809882.9T DK2782557T3 (en) 2011-11-23 2012-11-21 PHARMACEUTICAL FORMULATIONS
EA201491007A EA025389B1 (ru) 2011-11-23 2012-11-21 Лекарственные составы
SM20180595T SMT201800595T1 (it) 2011-11-23 2012-11-21 Formulazioni farmaceutiche
MX2014006278A MX353446B (es) 2011-11-23 2012-11-21 Formulaciones farmaceuticas.
PL12809882T PL2782557T3 (pl) 2011-11-23 2012-11-21 Formulacje farmaceutyczne
AU2012340759A AU2012340759C1 (en) 2011-11-23 2012-11-21 Pharmaceutical formulations
UAA201403227A UA115039C2 (uk) 2011-11-23 2012-11-21 Фармацевтичні композиції
KR1020147013457A KR102091295B1 (ko) 2011-11-23 2012-11-21 제약 제제
ZA2014/02418A ZA201402418B (en) 2011-11-23 2014-04-02 Pharmaceutical formulations
TNP2014000145A TN2014000145A1 (en) 2011-11-23 2014-04-08 Pharmaceutical formulations
IL232305A IL232305B (en) 2011-11-23 2014-04-28 Pharmacy preparations
MA37033A MA35716B1 (fr) 2011-11-23 2014-05-15 Formulations pharmaceutiques
PH12014501157A PH12014501157A1 (en) 2011-11-23 2014-05-22 Pharmaceutical formulations
US15/179,190 US9763941B2 (en) 2011-11-23 2016-06-10 Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
US15/452,239 US10258622B2 (en) 2011-11-23 2017-03-07 Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate
US15/921,306 US10561654B2 (en) 2011-11-23 2018-03-14 Pharmaceutical formulations of (S)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
CY20181101222T CY1121421T1 (el) 2011-11-23 2018-11-20 Φαρμακοτεχνικες μορφες

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161563229P 2011-11-23 2011-11-23
US61/563,229 2011-11-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/359,121 A-371-Of-International US9387208B2 (en) 2011-11-23 2012-11-21 Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
US15/179,190 Continuation US9763941B2 (en) 2011-11-23 2016-06-10 Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate

Publications (1)

Publication Number Publication Date
WO2013078264A1 true WO2013078264A1 (en) 2013-05-30

Family

ID=47501412

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/066185 Ceased WO2013078264A1 (en) 2011-11-23 2012-11-21 Pharmaceutical formulations

Country Status (38)

Country Link
US (4) US9387208B2 (https=)
EP (2) EP3449911B8 (https=)
JP (2) JP6216325B2 (https=)
KR (1) KR102091295B1 (https=)
CN (2) CN103945831A (https=)
AR (1) AR088936A1 (https=)
AU (1) AU2012340759C1 (https=)
BR (1) BR112014011981B8 (https=)
CA (1) CA2856406C (https=)
CL (1) CL2014001337A1 (https=)
CO (1) CO6940426A2 (https=)
CY (1) CY1121421T1 (https=)
DK (1) DK2782557T3 (https=)
EA (1) EA025389B1 (https=)
EC (1) ECSP23034537A (https=)
ES (2) ES3037966T3 (https=)
GT (1) GT201400100A (https=)
HR (1) HRP20181896T1 (https=)
HU (1) HUE040370T2 (https=)
IL (1) IL232305B (https=)
JO (1) JO3493B1 (https=)
LT (1) LT2782557T (https=)
MA (1) MA35716B1 (https=)
MX (1) MX353446B (https=)
MY (1) MY172729A (https=)
PE (1) PE20141994A1 (https=)
PH (1) PH12014501157A1 (https=)
PL (1) PL2782557T3 (https=)
PT (1) PT2782557T (https=)
RS (1) RS58048B1 (https=)
SG (1) SG11201401260QA (https=)
SI (1) SI2782557T1 (https=)
SM (1) SMT201800595T1 (https=)
TN (1) TN2014000145A1 (https=)
TW (1) TWI649098B (https=)
UA (1) UA115039C2 (https=)
WO (1) WO2013078264A1 (https=)
ZA (1) ZA201402418B (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2615986C1 (ru) * 2016-02-25 2017-04-12 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения
WO2017210538A1 (en) 2016-06-03 2017-12-07 Giordano Caponigro Pharmaceutical combinations
EP3302565B1 (en) 2015-06-04 2019-11-06 Pfizer Inc Solid dosage forms of palbociclib
WO2022074011A1 (en) 2020-10-05 2022-04-14 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
USRE49556E1 (en) 2009-08-28 2023-06-20 Array Biopharma Inc. Compounds and compositions as protein kinase inhibitors
WO2023239337A1 (en) * 2022-06-08 2023-12-14 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi A pharmaceutical composition comprising palbociclib
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2622015C2 (ru) 2011-11-11 2017-06-08 Новартис Аг Способ лечения пролиферативного заболевания
SI2782557T1 (sl) 2011-11-23 2019-02-28 Array Biopharma, Inc., Farmacevtske formulacije
CN105816437B (zh) 2016-03-29 2018-08-03 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法
CN106000220A (zh) * 2016-06-30 2016-10-12 东华大学 一种含化学试剂的有机溶剂崩解片的制备方法与应用
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
CN114557977A (zh) * 2022-02-16 2022-05-31 北京康立生医药技术开发有限公司 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法
WO2025262137A1 (en) * 2024-06-21 2025-12-26 Nanoform Finland Oyj Formulations comprising crystalline nanosized encorafenib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025927A1 (en) * 2009-08-28 2011-03-03 Irm Llc Compounds and compositions as protein kinase inhibitors

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5475888A (en) 1977-11-29 1979-06-18 Jiyasuko Kk Surgical laser
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
CA2231050A1 (en) 1995-09-07 1997-03-13 Biovail International Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
AU754830C (en) 1997-05-22 2004-02-12 G.D. Searle Llc Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
EP1239831B1 (en) 1999-12-23 2012-10-31 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
ATE374753T1 (de) 2001-12-21 2007-10-15 Vernalis Cambridge Ltd 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
MXPA06007820A (es) 2004-01-09 2006-09-01 Novartis Ag Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina como inhibidores de igf-ir.
RU2401265C2 (ru) 2004-06-10 2010-10-10 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы
US7608635B2 (en) 2005-08-12 2009-10-27 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
EP1919460A2 (en) 2005-08-22 2008-05-14 Novartis AG Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent
US20080242667A1 (en) 2005-08-26 2008-10-02 Smithkline Beecham Corporation Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
WO2007105058A2 (en) 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
WO2007123892A2 (en) 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
CN103739595A (zh) 2006-10-02 2014-04-23 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
JP2010505859A (ja) 2006-10-06 2010-02-25 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤およびそれを使用するための方法
EP2089003A1 (en) 2006-11-09 2009-08-19 Abbott GmbH & Co. KG Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
US20090022789A1 (en) * 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
WO2009016460A2 (en) 2007-08-01 2009-02-05 Pfizer Inc. Pyrazole compounds and their use as raf inhibitors
UA100865C2 (ru) * 2007-10-19 2013-02-11 Эбботт Гмбх Унд Ко. Кг Твердый дисперсный продукт лекарственных средств на основе n-арилмочевины
CN101861316B (zh) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
WO2009100176A2 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2009115572A2 (en) 2008-03-21 2009-09-24 Novartis Ag Novel heterocyclic compounds and uses therof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
PT2324008E (pt) 2008-07-24 2012-06-25 Nerviano Medical Sciences Srl 3,4-diarilpirazoles como inibidores da proteína quinase
CN102123987A (zh) 2008-07-28 2011-07-13 吉里德科学公司 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物
US8778929B2 (en) 2008-09-29 2014-07-15 Boehringer Ingelheim International Gmbh Substituted heteroaryl inhibitors of B-RAF
CA2737400C (en) * 2008-10-07 2016-11-22 Astrazeneca Uk Limited Pharmaceutical formulation 514
WO2010056662A1 (en) 2008-11-11 2010-05-20 University Of Washington Activated wnt-beta-catenin signaling in melanoma
ES2422263T3 (es) 2008-12-19 2013-09-10 Nerviano Medical Sciences Srl Pirazoles bicíclicos como inhibidores de la proteinquinasa
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
US8546413B2 (en) 2009-06-15 2013-10-01 Nerviano Medical Sciences S.R.L. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
CN104958294A (zh) 2010-01-27 2015-10-07 内尔维安诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物
CN102918034B (zh) 2010-03-30 2015-06-03 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
EP2601185B1 (en) 2010-08-03 2015-10-07 Nerviano Medical Sciences S.r.l. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
CA2829263C (en) 2011-03-21 2020-05-12 Valcuria Ab A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof.
PH12013502523A1 (en) 2011-06-14 2019-10-11 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
SI2782557T1 (sl) 2011-11-23 2019-02-28 Array Biopharma, Inc., Farmacevtske formulacije
JP2015536964A (ja) 2012-11-08 2015-12-24 ノバルティス アーゲー Ｂ−ｒａｆ阻害剤とヒストン脱アセチル化酵素阻害剤を含む医薬組合せおよび増殖性疾患の治療におけるそれらの使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025927A1 (en) * 2009-08-28 2011-03-03 Irm Llc Compounds and compositions as protein kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DHIRENDRA K., LEWIS S., UDUPA N., ATIN K.: "Solid dispersions: A review", PAK J. PHARM .SCI., vol. 22, no. 2, 30 April 2009 (2009-04-30), pages 234 - 246, XP002692483 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49556E1 (en) 2009-08-28 2023-06-20 Array Biopharma Inc. Compounds and compositions as protein kinase inhibitors
EP3302565B1 (en) 2015-06-04 2019-11-06 Pfizer Inc Solid dosage forms of palbociclib
US11065250B2 (en) 2015-06-04 2021-07-20 Pfizer Inc. Solid dosage forms of palbociclib
RU2615986C1 (ru) * 2016-02-25 2017-04-12 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения
WO2017146604A1 (ru) * 2016-02-25 2017-08-31 Акционерное Общество "Р-Фарм" (Ао "Р-Фарм") Замещенные метил (2-{4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1н-пиразол-4-ил]-пиримидин-2-иламино}-этил)карбаматы, способ их получения и применения
WO2017210538A1 (en) 2016-06-03 2017-12-07 Giordano Caponigro Pharmaceutical combinations
US10485788B2 (en) 2016-06-03 2019-11-26 Array Biopharma Inc. Pharmaceutical combinations
US11376239B2 (en) 2016-06-03 2022-07-05 Array Biopharma Inc Pharmaceutical combinations
WO2022074011A1 (en) 2020-10-05 2022-04-14 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
WO2023239337A1 (en) * 2022-06-08 2023-12-14 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi A pharmaceutical composition comprising palbociclib
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Also Published As

Publication number Publication date
TWI649098B (zh) 2019-02-01
CN105708819B (zh) 2020-12-29
MX2014006278A (es) 2014-07-09
AU2012340759B2 (en) 2016-04-28
DK2782557T3 (en) 2018-12-10
HUE040370T2 (hu) 2019-03-28
MA35716B1 (fr) 2014-12-01
JP6216325B2 (ja) 2017-10-18
EP2782557A1 (en) 2014-10-01
CY1121421T1 (el) 2020-05-29
SG11201401260QA (en) 2014-07-30
LT2782557T (lt) 2018-12-27
SMT201800595T1 (it) 2019-01-11
CA2856406C (en) 2020-06-23
JO3493B1 (ar) 2020-07-05
US20140309250A1 (en) 2014-10-16
RS58048B1 (sr) 2019-02-28
PH12014501157B1 (en) 2014-08-11
HK1197024A1 (en) 2015-01-02
US20190054086A1 (en) 2019-02-21
TN2014000145A1 (en) 2015-09-30
IL232305B (en) 2019-06-30
US20160279129A1 (en) 2016-09-29
MY172729A (en) 2019-12-11
SI2782557T1 (sl) 2019-02-28
AR088936A1 (es) 2014-07-16
PT2782557T (pt) 2018-11-26
ES2695099T3 (es) 2019-01-02
BR112014011981A8 (pt) 2018-07-31
BR112014011981A2 (pt) 2017-05-30
EA201491007A1 (ru) 2014-08-29
ES3037966T3 (en) 2025-10-08
NZ623628A (en) 2016-05-27
US9763941B2 (en) 2017-09-19
EA025389B1 (ru) 2016-12-30
US10258622B2 (en) 2019-04-16
KR20140095500A (ko) 2014-08-01
HRP20181896T1 (hr) 2019-02-22
CN103945831A (zh) 2014-07-23
EP2782557B1 (en) 2018-09-12
KR102091295B1 (ko) 2020-03-19
ZA201402418B (en) 2015-03-25
EP3449911B1 (en) 2025-06-18
US10561654B2 (en) 2020-02-18
JP2018035171A (ja) 2018-03-08
ECSP23034537A (es) 2023-08-31
GT201400100A (es) 2017-09-28
AU2012340759C1 (en) 2019-11-28
MX353446B (es) 2018-01-12
EP3449911B8 (en) 2025-07-23
EP3449911A1 (en) 2019-03-06
BR112014011981B8 (pt) 2022-07-19
CN105708819A (zh) 2016-06-29
JP2015501808A (ja) 2015-01-19
IL232305A0 (en) 2014-06-30
BR112014011981B1 (pt) 2020-11-17
CO6940426A2 (es) 2014-05-09
CA2856406A1 (en) 2013-05-30
PL2782557T3 (pl) 2019-03-29
PE20141994A1 (es) 2014-12-24
UA115039C2 (uk) 2017-09-11
CL2014001337A1 (es) 2014-10-24
PH12014501157A1 (en) 2014-08-11
AU2012340759A1 (en) 2014-05-29
TW201328722A (zh) 2013-07-16
US20170202837A1 (en) 2017-07-20
US9387208B2 (en) 2016-07-12

Similar Documents

Publication Publication Date Title
US10561654B2 (en) Pharmaceutical formulations of (S)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
US11679105B1 (en) Pharmaceutical compositions of cabozantinib
CN110114063B (zh) 鲁拉西酮固体分散体及其制备方法
JP2015501808A5 (https=)
HK40005622A (en) Pharmaceutical formulations
HK1197024B (en) Pharmaceutical formulations
NZ623628B2 (en) Solid oral pharmaceutical formulations comprising amorphous (S)-methyl (1- ((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropy1-1H-pyrazo1-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (Compound A)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12809882

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012809882

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 232305

Country of ref document: IL

Ref document number: 14090466

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 000678-2014

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: 14359121

Country of ref document: US

ENP Entry into the national phase

Ref document number: 20147013457

Country of ref document: KR

Kind code of ref document: A

Ref document number: 2856406

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2014543550

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2014001337

Country of ref document: CL

Ref document number: 12014501157

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/006278

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2012340759

Country of ref document: AU

Date of ref document: 20121121

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2014000352

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: A201403227

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 201491007

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014011981

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014011981

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140519